Cardiovascular biomarkers serve as reproducible, sensitive, and minimally invasive tools for risk stratification, early detection of cardiotoxicity, and prognostic assessment in cancer patients.
What is the role of cardiovascular biomarkers in risk stratification and early detection of chemotherapy-induced cardiotoxicity in cancer patients?
Cardiovascular biomarkers are useful, minimally invasive tools for risk stratification and early detection of cardiotoxicity in cancer patients undergoing antineoplastic treatments.
Serum biomarkers represent a reproducible, sensitive, minimally invasive and inexpensive method to explore possible adverse cardiovascular effects of antineoplastic treatments. They are useful tools in risk stratification, the early detection of cardiotoxicity and the follow-up and prognostic assessment of cancer patients. In this literature review, we aim at describing the current state of knowledge on the meaning and the usefulness of cardiovascular biomarkers in patients with cancer; analyzing the intricate relationship between cancer and cardiovascular disease (especially HF) and how this affects cardiovascular and tumor biomarkers; exploring the role of cardiovascular biomarkers in the risk stratification and in the identification of chemotherapy-induced cardiotoxicity; and providing a summary of the novel potential biomarkers in this clinical setting.
Attanasio et al. (Wed,) conducted a review in Cancer and chemotherapy-induced cardiotoxicity. Cardiovascular biomarkers was evaluated. Cardiovascular biomarkers serve as reproducible, sensitive, and minimally invasive tools for risk stratification, early detection of cardiotoxicity, and prognostic assessment in cancer patients.